SAR446268A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

Sponsor:

Sanofi

Code:

NCT06844214

Conditions

Myotonic Dystrophy

Eligibility Criteria

Sex: All

Age: 10 - 55

Healthy Volunteers: Not accepted

Interventions

SAR446268

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Sanofi on 2026-06-01.